drugset / Trial / NCT04421820
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Non-randomizedSingle-groupOpen-labelTreatment
Summary
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
Timeline
- Start
- 2020-08-28
- Primary completion
- 2026-06-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BOLD-100 | Small molecule | 500 mg/m2 | Intravenous |
| Subject | BOLD-100 | Small molecule | 625 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |